48 results
Page 2 of 3
8-K
EX-99.1
i0q spy4j58b5zksx
5 May 20
Fate Therapeutics Announces Changes to its Board of Directors
4:03pm
8-K
EX-99.1
q9iar 7miq2r4non
17 Jul 19
Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors
4:03pm
424B5
ndtbljcgw6 nqt00ook
21 Sep 18
Prospectus supplement for primary offering
4:41pm
424B5
8q50t
20 Sep 18
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
1b5w4s gszrca
6 Aug 18
Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress
4:10pm
8-K
vn1u6gy verq6
18 May 18
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
4:05pm
8-K
EX-99.1
cckfsx
18 May 18
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
4:05pm
8-K
EX-99.1
4inkbb54ncsfdul jz8
17 Nov 14
Results of Operations and Financial Condition
12:00am